Taxing Transactions: UnitedHealth’s Dispute Exposes a Larger Pattern

The Internal Revenue Service (IRS) is scrutinizing how UnitedHealth Group allocated profits between its US operations and foreign subsidiaries from 2017 through 2020. At the heart of this dispute is the IRS’s proposal to increase UnitedHealth’s taxable income over these transactions.

This development highlights the complex world of transfer pricing, where multinational corporations allocate profits between their domestic and foreign operations. The IRS has been increasing its scrutiny of transfer pricing by US-based multinationals since the Obama administration. In high-profile cases involving companies like Coca-Cola and Meta, the agency has secured significant tax payments in some instances but faced rejection or lower amounts in others.

UnitedHealth’s case is unique because it doesn’t provide sufficient details to estimate the potential exposure. However, experts note that the company’s gross unrecognized tax benefits rose to $5.6 billion at the end of 2020. UnitedHealth has stated that it will “vigorously contest” the IRS’s proposed adjustments.

The transfer pricing game has become increasingly complex over the years, with companies and their advisors finding creative ways to justify allocation strategies. Section 482 of the tax code allows the IRS to adjust a company’s taxable income if it believes transactions between related businesses were not fairly priced. However, determining fair value can be challenging when there’s no unrelated third party to compare against.

This raises important questions about the role of transfer pricing in shaping global economic policy and governments’ ability to collect revenue from multinational corporations. The IRS’s scrutiny of UnitedHealth’s transactions is just one battle in an ongoing war between tax authorities and companies seeking to minimize their tax liabilities.

The outcome of this dispute will be crucial for policymakers, who must consider the broader implications. Transfer pricing disputes can outlast multiple corporate and presidential administrations, as seen with Medtronic’s long-running battle over its 2005 and 2006 tax years. The stakes are high, and the outcome could have significant consequences for companies, governments, and taxpayers.

The UnitedHealth-IRS dispute is a microcosm of a larger pattern: multinational corporations seeking to minimize their tax liabilities through complex transfer pricing strategies while tax authorities attempt to enforce compliance. As the world grapples with issues like global income inequality and corporate accountability, this case serves as a stark reminder of the need for transparency and fairness in international taxation.

The IRS will continue to scrutinize transfer pricing practices to ensure that multinational corporations pay their fair share of taxes. As the stakes grow higher, it’s essential that policymakers, corporate leaders, and tax experts engage in a nuanced discussion about the role of transfer pricing in shaping global economic policy.